Spero Therapeutics (SPRO) Scheduled to Post Quarterly Earnings on Wednesday

Spero Therapeutics (NASDAQ:SPRO) will be posting its quarterly earnings results after the market closes on Wednesday, May 15th. Analysts expect Spero Therapeutics to post earnings of ($0.06) per share for the quarter.

Spero Therapeutics (NASDAQ:SPRO) last announced its earnings results on Wednesday, March 13th. The company reported $0.96 earnings per share for the quarter, beating the consensus estimate of ($0.18) by $1.14. The firm had revenue of $73.52 million for the quarter, compared to the consensus estimate of $19.40 million. Spero Therapeutics had a return on equity of 38.54% and a net margin of 21.98%. On average, analysts expect Spero Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Spero Therapeutics Price Performance

Shares of Spero Therapeutics stock opened at $1.67 on Thursday. The business’s fifty day moving average price is $1.64 and its two-hundred day moving average price is $1.44. The company has a market capitalization of $90.00 million, a P/E ratio of 3.98 and a beta of 0.62. Spero Therapeutics has a 1-year low of $0.99 and a 1-year high of $1.98.

Analyst Ratings Changes

Several equities analysts have recently issued reports on SPRO shares. HC Wainwright reiterated a “buy” rating and set a $7.00 price target on shares of Spero Therapeutics in a research report on Monday, March 18th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Spero Therapeutics in a research report on Thursday, April 4th.

About Spero Therapeutics

Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease.